Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. 2008

Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
Laboratory of Oncology, G. Gaslini Children's Hospital, Genoa, Italy. fabiomorandi@ospedale-gaslini.ge.it

Human mesenchymal stem cells (MSC) are immunosuppressive and poorly immunogenic but may act as antigen-presenting cells (APC) for CD4(+) T-cell responses; here we have investigated their ability to serve as APC for in vitro CD8(+) T-cell responses. MSC pulsed with peptides from viral antigens evoked interferon (IFN)-gamma and Granzyme B secretion in specific cytotoxic T lymphocytes (CTL) and were lysed, although with low efficiency. MSC transfected with tumor mRNA or infected with a viral vector carrying the Hepatitis C virus NS3Ag gene induced cytokine release but were not killed by specific CTL, even following pretreatment with IFN-gamma. To investigate the mechanisms involved in MSC resistance to CTL-mediated lysis, we analyzed expression of human leukocyte antigen (HLA) class I-related antigen-processing machinery (APM) components and of immunosuppressive HLA-G molecules in MSC. The LMP7, LMP10, and ERp57 components were not expressed and the MB-1 and zeta molecules were downregulated in MSC either unmanipulated or pretreated with IFN-gamma. Surface HLA-G was constitutively expressed on MSC but was not involved in their protection from CTL-mediated lysis. MSC supernatants containing soluble HLA-G (sHLA-G) inhibited CTL-mediated lysis, whereas those lacking sHLA-G did not. The role of sHLA-G in such inhibition was unambiguously demonstrated by partial restoration of lysis following sHLA-G depletion from MSC supernatants. In conclusion, human MSC can process and present HLA class I-restricted viral or tumor antigens to specific CTL with a limited efficiency, likely because of some defects in APM components. However, they are protected from CTL-mediated lysis through a mechanism that is partly sHLA-G-dependent.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000938 Antigen-Presenting Cells A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors. Accessory Cells, Immunologic,Antigen-Presenting Cell,Immunologic Accessory Cells,Accessory Cell, Immunologic,Cell, Immunologic Accessory,Cells, Immunologic Accessory,Immunologic Accessory Cell,Antigen Presenting Cell,Antigen Presenting Cells,Cell, Antigen-Presenting,Cells, Antigen-Presenting
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral

Related Publications

Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
September 2003, Journal of immunology (Baltimore, Md. : 1950),
Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
November 2006, Experimental hematology,
Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
December 2000, International journal of cancer,
Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
May 2001, Journal of immunology (Baltimore, Md. : 1950),
Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
March 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
January 2005, Journal of biomedical science,
Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
July 1984, Journal of immunology (Baltimore, Md. : 1950),
Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
August 2001, Biochemical and biophysical research communications,
Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
April 1986, Cellular immunology,
Fabio Morandi, and Lizzia Raffaghello, and Giovanna Bianchi, and Francesca Meloni, and Annalisa Salis, and Enrico Millo, and Soldano Ferrone, and Vincenzo Barnaba, and Vito Pistoia
January 2000, International journal of cancer,
Copied contents to your clipboard!